Results 1 to 10 of about 96 (70)

Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess

Human Vaccines and Immunotherapeutics, 2022
This study assessed adverse events following immunizations (AEFIs) reported on COVID-19 vaccines in VigiAccess and determined the reporting trends across all continents of the world. The study was cross-sectional quantitative in design.
Joseph Attakorah, Peter Yamoah, Neelaveni Padayachee   +2 more
exaly   +2 more sources

Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries

Case Reports in Nephrology, 2020
Direct oral anticoagulants (DOACs) are among the most commonly prescribed medications, and DOAC-associated kidney dysfunction may be a problem that is underrecognized by clinicians. We report on the case of an 82-year-old patient who, two weeks after the
Gisela Marcelino, Ould Maouloud Hemett, Eric Descombes   +2 more
doaj   +2 more sources

Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess

Frontiers in Pharmacology, 2023
Introduction: Tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etanercept, golimumab, and certolizumab pegol) have revolutionized the treatment of severe immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn’s ...
Hongbo Zhou, Ruxu You, You Ruxu
exaly   +3 more sources

Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess

Frontiers in Pharmacology
BackgroundThis study assessed the adverse drug reactions (ADRs) associated with HDAC inhibitors using the VigiAccess database maintained by the World Health Organization (WHO).
Yumeng Lin, Lin Yumeng
exaly   +3 more sources

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

Frontiers in Pharmacology
BackgroundLecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence.
Haoxiang Hu, Yunhan Zhao, Jiesheng Mao, Jianghai He, Yihan Zhang, Hongyu Ye, Xiaokai Yang   +6 more
exaly   +3 more sources

DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess

Frontiers in Pharmacology
IntroductionDNA methylation inhibitors (azacitidine, decitabine) have revolutionized the treatment dilemma of myelodysplastic syndromes (MDS), a group of malignant hematopoietic disorders.
Wang Haojie
exaly   +3 more sources

Real-world safety of tirofiban: a disproportionality analysis using data from FAERS and WHO-VigiAccess

Frontiers in Pharmacology
ObjectiveThis study aimed to detect tirofiban-related adverse event (AE) signals using the FAERS and WHO-VigiAccess databases to support safer clinical use.MethodsAll tirofiban-related AE reports were retrieved from FAERS (2004Q1 to 2024Q4) and WHO ...
Zheng Yifan
exaly   +3 more sources

Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess

Frontiers in Pharmacology
IntroductionFinerenone is a novel non-steroidal mineralocorticoid receptor antagonist that has shown promise in the treatment of chronic kidney disease and heart failure.
Boda Zhou, Zhou Boda
exaly   +3 more sources

The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases

Frontiers in Pharmacology
BackgroundAzacitidine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It acts as a cytosine analog and DNA methyltransferase inhibitor, inducing DNA hypomethylation to reverse epigenetic modifications and restore normal ...
Ding Juan, Guo Linlin, Linlin Guo
exaly   +3 more sources

The characteristics of adverse reactions of three anti-prostate cancer drugs based on Vigiaccess database and bibliometric analysis

Frontiers in Pharmacology
BackgroundAndrogen antagonists, including apalutamide, darolutamide, and enzalutamide, play a crucial role in the treatment of prostate cancer.
Jianqing Wang, Liwei Zhang, Wang Jianqing   +2 more
exaly   +3 more sources